FibroBiologics' Form D confirms Peak One debenture as Rule 506(b) offering, fully sold

FibroBiologics, Inc. filed a Form D on October 12, 2026, disclosing details of the convertible debenture financing with Peak One Opportunity Fund, L.P. that closed earlier in the month. The offering includes a convertible debenture in the principal amount of $1,200,000 and 125,000 restricted shares, with a total offering amount of $1,200,000 and total amount sold of $1,200,000, leaving $0 remaining to be sold.¹

The filing shows a total of one investor has already invested in the offering.¹ The date of first sale was listed as October 7, 2026.¹ FibroBiologics claimed the Rule 506(b) exemption for the offering.¹ The minimum investment accepted from any outside investor was listed as $0.¹

The filing confirms the debenture is convertible following an event of default at a fixed conversion rate of $0.78 per share.¹ FibroBiologics said it intends to use net proceeds from the offering for working capital and general corporate purposes.¹

As previously reported, the underlying securities purchase agreement was signed October 7, 2026 and the offering closed October 8, 2026. The debenture was sold to Peak One for a purchase price of $1,020,000, representing an original issue discount of fifteen percent.² The debenture matures on October 8, 2027, accrues interest at an annual rate of 0%, and is only convertible following an Event of Default at a fixed conversion price of $0.78 per share.² Under Nasdaq rules, the company may not issue more than 1,671,094 shares under the SPA and the Debenture without stockholder approval.²